drugset / Trial / NCT05183347

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

NCT05183347

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male Japanese subjects following oral administration of single rising doses and multiple doses.

Timeline

Start
2022-02-04
Primary completion
2022-07-27
Completion
2022-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1291583 Unknown Oral

Indications

No indication recorded.